A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes (ELDERLY-T)
Study Overview
Primary objective:
- Glycemic control after initiation or switch to insulin glargine 300 U/ml in everyday clinical practice
Secondary objective:
- Treatment satisfaction
Study details
Study duration per participant is expected to be approximately 24 weeks
Eligibility Criteria
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Type 2 Diabetes Mellitus (T2DM)
-
Age: 75 Years
-
Gender: All
Inclusion Criteria:
- Type 2 diabetes mellitus (T2DM) with oral antidiabetic drug (OAD) ± Glucagon-like-peptide-1 receptor agonist (GLP-1-RA) ± basal insulin (other than insulin glargine 300 U/ml)
- Age ≥75 years incl. patients from outpatient and inpatient care forms
- Glycohaemoglobin (Hba1c) ≥8.0% and ≤11.0%
- Inadequate glycaemic control (HbA1c), defined by the treating physician
- Ability and willingness to perform fasting blood glucose (BG) measurements themselves or with the support of third parties
- Signed consent form
Exclusion Criteria:
- Type 1 diabetes mellitus
- Age <75 years
- Contraindications to insulin glargine 300 U/ml
- Short-acting insulin in medication
- Current participation in clinical research
- Life expectancy <1 year
- Known alcohol or drug abuse
- Mini Mental State Examination Score ≤19
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Updated on
12 Apr 2024.
Study ID: NCT05607160